亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience

医学 氟达拉滨 内科学 单中心 髓系白血病 不利影响 肿瘤科 威尼斯人 克拉屈滨 化疗 耐火材料(行星科学) 移植 入射(几何) 阿糖胞苷 米托蒽醌 髓样 回顾性队列研究 白血病 挽救疗法 外科 淋巴瘤 嘌呤类似物 干细胞 中性粒细胞减少症 多发性骨髓瘤 造血干细胞移植
作者
Jose Tinajero,Dat Ngo,Brian Lee,Hoim Kim,Brian J. Ball,Paul Koller,Idoroenyi Usua Amanam,Hoda Pourhassan,Haris Ali,Salman Otoukesh,Amandeep Salhotra,Amanda L. Blackmon,Karamjeet Sandhu
出处
期刊:Journal of Oncology Pharmacy Practice [SAGE Publishing]
卷期号:32 (3): 555-559 被引量:2
标识
DOI:10.1177/10781552251396885
摘要

ObjectiveIntensive chemotherapy combinations with venetoclax are being used more frequently for acute myeloid leukemia (AML). In May 2022, a critical shortage of fludarabine prompted cladribine substitution at several institutions in the United States. FLAG-Ida-Ven and CLIA-Ven are similar IC regimens using different purine analogues, potentially with different efficacy and toxicity. To describe the patient population, outcomes, and toxicities of patients receiving FLAG-Ida-Ven and CLIA-Ven.Data SourcesA retrospective analysis of patients over 18 years with AML who received FLAG-Ida-Ven or CLIA-Ven for relapsed/refractory AML (R/R AML) at the City of Hope between December 2020 and January 2023.Data SummaryThere were 31 patients who received FLAG-Ida-Ven; 8 patients received CLIA-Ven. Patients were identified using ICD-10 code for AML and documented administration of medications. Most patients included were male with de novo AML with ELN adverse risk AML. Median age was 53 years (20-78) for FLAG-Ida-Ven and 47.5 years (23-69) for CLIA-Ven. Prior exposure to venetoclax based therapy was common (61.3% vs 50%). The ORR (overall response rate) in FLAG-Ida-Ven and CLIA-Ven was 46.7% and 75%, of which 86% vs 83% were MRD negative, respectively. There were 42% (n = 13) and 50% (n = 4) of patients who were able to proceed to allogeneic stem cell transplant in the FLAG-Ida-Ven and CLIA-Ven with median time to transplant being 89 vs 132 days respectively.Regarding safety, CLIA-Ven had a higher incidence of grade 3 or 4 non-hematologic adverse events, 6% vs 50% respectively. Survival from therapy initiation at 6 months was 48.4% vs 75%.ConclusionConsistent with the literature, it appears that the activity between FLAG-Ida-Ven and CLIA-Ven are comparable, however FLAG-Ida-Ven may have a more tolerable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
6秒前
12秒前
内向的紫槐完成签到,获得积分10
15秒前
17秒前
沉静问芙完成签到,获得积分10
21秒前
小黑桃完成签到,获得积分10
25秒前
jf完成签到 ,获得积分10
30秒前
35秒前
cc发布了新的文献求助10
38秒前
科研通AI6.4的应助被祈愿采纳,获得10
38秒前
qiao完成签到,获得积分10
41秒前
Maestro_S的应助被cc采纳,获得10
42秒前
45秒前
jen完成签到 ,获得积分10
46秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
49秒前
斯文败类的应助被DRJ采纳,获得10
49秒前
华仔的应助被科研通管家采纳,获得10
49秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
49秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
49秒前
科目三的应助被科研通管家采纳,获得30
50秒前
Ava的应助被科研通管家采纳,获得10
50秒前
Isaac完成签到,获得积分10
50秒前
SGD完成签到,获得积分10
51秒前
corleeang完成签到 ,获得积分10
54秒前
丰富夏菡完成签到,获得积分10
56秒前
SGD发布了新的文献求助10
57秒前
null的应助被Ella采纳,获得10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
1分钟前
azhiyuan完成签到,获得积分10
1分钟前
搜集达人的应助被DRJ采纳,获得10
1分钟前
科研通AI6.4的应助被SUNny采纳,获得10
1分钟前
九灶完成签到 ,获得积分10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
1分钟前
null的应助被Ella采纳,获得10
1分钟前
小黑桃发布了新的文献求助10
1分钟前
1分钟前
沉默的元枫完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165939
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749898
捐赠科研通 7756692
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553385
邀请新用户注册赠送积分活动 2473623